AQR Capital Management
KRYS icon

AQR Capital Management’s Krystal Biotech KRYS Stock Holding History

AQR Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.65M Sell
14,114
-43
-0.3% -$11.4K ﹤0.01% 1945
2025
Q4 		$3.49M Sell
14,157
-5,976
-30% -$1.26M ﹤0.01% 1788
2025
Q3 		$3.55M Buy
20,133
+8,165
+68% +$1.22M ﹤0.01% 1652
2025
Q2 		$1.65M Sell
11,968
-163
-1% -$23.9K ﹤0.01% 1904
2025
Q1 		$2.19M Buy
12,131
+2,792
+30% +$470K ﹤0.01% 1563
2024
Q4 		$1.46M Buy
9,339
+989
+12% +$175K ﹤0.01% 1688
2024
Q3 		$1.52M Buy
8,350
+763
+10% +$147K ﹤0.01% 1629
2024
Q2 		$1.39M Buy
7,587
+1,551
+26% +$260K ﹤0.01% 1614
2024
Q1 		$1.07M Buy
6,036
+1,734
+40% +$241K ﹤0.01% 1658
2023
Q4 		$534K Buy
4,302
+288
+7% +$31.9K ﹤0.01% 1852
2023
Q3 		$466K Sell
4,014
-437
-10% -$53.3K ﹤0.01% 1871
2023
Q2 		$523K Buy
4,451
+507
+13% +$51.8K ﹤0.01% 1774
2023
Q1 		$316K Buy
3,944
+236
+6% +$18.5K ﹤0.01% 1928
2022
Q4 		$294K Buy
+3,708
New +$275K ﹤0.01% 1978
2020
Q3 		– Sell
-8,377
Closed -$347K – 2231
2020
Q2 		$347K Sell
8,377
-3,920
-32% -$189K ﹤0.01% 1855
2020
Q1 		$532K Buy
12,297
+2,448
+25% +$128K ﹤0.01% 1565
2019
Q4 		$545K Sell
9,849
-681
-6% -$33.4K ﹤0.01% 1727
2019
Q3 		$366K Buy
10,530
+1,458
+16% +$65.2K ﹤0.01% 1858
2019
Q2 		$365K Buy
+9,072
New +$297K ﹤0.01% 1817

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management's KRYS Position: Q1 2026 in Review

AQR Capital Management reduced its Krystal Biotech (KRYS) stake by 0.3% in Q1 2026, selling an estimated $11.4K and leaving 14,114 shares worth $3.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1945.

AQR Capital Management first reported a position in KRYS in Q2 2019 and has held it in 19 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • AQR Capital Management held 14,114 shares of Krystal Biotech worth $3.65M as of Q1 2026.
  • AQR Capital Management sold 43 Krystal Biotech shares in Q1 2026, an estimated $11.4K.
  • Krystal Biotech made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1945 holding.
  • AQR Capital Management first reported a position in Krystal Biotech in Q2 2019 and has held it in 19 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.